Discontinuation Criteria for Albumin and Octreotide in Hepatorenal Syndrome

Treatment Duration Guidelines

Albumin and octreotide therapy should be discontinued when serum creatinine returns to baseline values or after a maximum treatment duration of 14 days if there is no response, as recommended by the American Association for the Study of Liver Diseases 1
The American Gastroenterological Association suggests continuing albumin for the entire duration of vasoconstrictor therapy, at a dose of 20-40 g/day 2, 3
Discontinue albumin when vasoconstrictor therapy is stopped, according to the American Association for the Study of Liver Diseases 1
Monitor for signs of volume overload during albumin administration, as excessive albumin may lead to respiratory failure, as warned by the American Gastroenterological Association 2

A complete response is defined as a final serum creatinine within 0.3 mg/dL from baseline value, with treatment continued for 24 hours after creatinine normalizes, as defined by the International Club of Ascites 4, 5
A partial response is characterized by regression of AKI stage with final serum creatinine ≥0.3 mg/dL from baseline, with treatment continued for the full 14-day course, as recommended by the American Association for the Study of Liver Diseases 1, 4

Track serum creatinine daily to assess treatment response, as recommended by the American Association for the Study of Liver Diseases 1
Monitor mean arterial pressure (MAP) - a sustained increase of 5-10 mmHg is associated with treatment response, according to the American Gastroenterological Association 3
Assess urine output - improvement suggests positive response, as indicated by the American Association for the Study of Liver Diseases 1
Watch for signs of volume overload from albumin administration, as warned by the American Gastroenterological Association 2

In patients with recurrence of HRS-AKI after treatment cessation, a repeat course of therapy should be given, as recommended by the International Club of Ascites 4
Patients with very high pretreatment creatinine values may need treatment longer than 14 days to reach baseline, according to the American Association for the Study of Liver Diseases 1

Even small reductions in serum creatinine are beneficial - every 1 mg/dL drop in creatinine is associated with a 27% reduction in mortality risk, as reported by the American Gastroenterological Association 2

Continuing therapy beyond 14 days without evidence of response increases risk of adverse effects without additional benefit, as warned by the American Association for the Study of Liver Diseases 1
Failure to monitor for volume overload from albumin administration can lead to respiratory complications, as cautioned by the American Gastroenterological Association 2
Not recognizing treatment failure early (by day 4) may unnecessarily prolong ineffective therapy, according to the American Association for the Study of Liver Diseases 1
Discontinuing treatment too early after initial response may lead to recurrence of HRS, as noted by the International Club of Ascites 4